Synergy wins U.S. approval for constipation drug (Jan 19)

(The Jan. 19 story corrects paragraph 9 to say Ironwood Pharma also sells Linzess in North America) (Reuters) – The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc’s drug to treat chronic idiopathic constipation (CIC). CIC, which affects 14 percent of the global population, is a type of gastrointestinal disorder where individuals have difficult and infrequent bowel movements. Trulance met the main goals of two late-stage studies in December on irritable bowel syndrome patients with constipation (IBS-C).
Go to Source